« Previous Article
Next Article »

Invited Review Open Access


Melatonin agonists for treatment of sleep and depressive disorders

Venkataramanujan Srinivasan, Daniel P. Cardinali, Seithikurippu R. Pandi-Perumal, Gregory M. Brown.

Cited by (9)

Abstract
Melatonin the hormone secreted by the pineal gland has been effective in improving sleep both in normal sleepers and insomniacs and has been used successfully in treating sleep and circadian rhythm sleep disorders. The lack of consistency in the reports published by the authors is attributed to the differential bioavailabilty and short half-life of melatonin.
Sleep disturbances are also prominent features of depressive disorders. To overcome this problem, melatonergic agonists with sleep promoting properties have been introduced in clinical practice. Ramelteon, the MT1/ MT2 melatonergic agonist, has been used in a large number of clinical trials involving chronic insomniacs and has been found effective in improving the total sleep time and sleep efficiency of insomniacs and has not manifested serious adverse effects.
The development of another MT1/MT2 melatonergic agonist agomelatine with antagonsim to 5-HT2c serotonin receptors has been found useful not only in treating sleep problems of patients but also as a first line antidepressant with earlier onset of actions in patients with major depressive disorder. An agonist for MT3 melatonin receptor has also been found effective in animal models of depression.

Key words: Agomelatine; Antidepressant; Insomnia; Major depressive disorder; Melatonergic agonist; Melatonin


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Export to
Export to
Related Records
 Articles by Venkataramanujan Srinivasan
Articles by Daniel P. Cardinali
Articles by Seithikurippu R. Pandi-Perumal
Articles by Gregory M. Brown
on Google
on Google Scholar
Article Statistics
 Viewed: 6352
Downloaded: 1949
Cited: 9

REFERENCES
1.Bubenik GA.Gastrointestinal melatonin:localization, function and clinical relevance.Dig Dis Sci 2002;47:2336-48.
[DOI via Crossref]    [Pubmed]   

2.Slominiski A, Wortsman J, Tobin DJ.The cutaneous serotonergic/melatonergic system;securing a place under the sun.FASEB J 2005;19:176-94.
[
DOI via Crossref]    [Pubmed]   

3.Carrillo-Vico A, Clavo JR, Abreu P, Lardone PJ, Garcia-Maurino S, Reiter RJ, Guerrero JM.Evidence of melatonin synthesis by human lymphocytes and its physiological significance:Possible role as intracrine, autocrine, and/or paracrine substance.FASEB J 2004;18:537-9.
[
Pubmed]   

4.Srinivasan V.The pineal gland:its physiological and pharmacological role.Ind J Physiol Pharmacol 1989;33:263-72.
[
Pubmed]   

5.Pandi-Perumal SR, Srinivasan V, Maestoni GJM, Cardinali DP, Poeggeler B Hardeland R.Melatonin:nature’s most versatile signal? FEBS J 2006;273:2813-38.
[
DOI via Crossref]    [Pubmed]   

6.Reppert SM, Weaver DR, Ebisawa T.Cloning and characterization of a mammalian receptor that mediates reproductive and circadian responses.Neuron 1994;13:1177-85.
[
DOI via Crossref]   

7.Reppert SM, Godson C, Mahle CD, Weaver DR, Slaughenhaupt SA, Gusella JF.Molecular characterization of a second melatonin receptor expressed in human retina and brain.The Mel1b melatonin receptor.Proc Natl Acad Sci USA, 1995;92:8734-8.
[
DOI via Crossref]   

8.von Gall C, Stehle JH, Weaver DR.Mammalian melatonin receptors:Molecular biology and signal transduction.Cell Tissue Res 2002;309:151-62.
[
DOI via Crossref]    [Pubmed]   

9.Turek FW, Gillette MU.Melatonin, sleep and circadian rhythms:rationale for development of specific melatonin agonists.Sleep Med 2004;5:523-32.
[
DOI via Crossref]    [Pubmed]   

10.Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben Shushan A, Ford I.Effects of exogenous melatonin on sleep:a meta analysis.Sleep Med Rev 2005;9:41-50.
[
DOI via Crossref]    [Pubmed]   

11.Srinivasan V, Smits G, KayumovL, Pandi-Perumal, SR, Cardinali DP, Thorpy MJ.Melatonin in circadian rhythm sleep disorders.In:Cardinali DP, Pandi-Perumal SR(eds) Neuroendocrine correlates of sleep/wakefulness.Springer, New York, pp 269-294, 2006.
[
DOI via Crossref]   

12.Dolberg OT, Hirschmann S, Grunhaus L.Melatonin for the treatment of sleep disturbances in major depressive disorder.Am J Psychiatry 1998;155:1119-21.
[
Pubmed]   

13.Lam RW.Sleep disturbances and depression:A challenge for antidepressants.Int Clin Psychopharmacol 2006;21(suppl 1):S25-9.
[
DOI via Crossref]    [Pubmed]   

14.Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, et al.Neurochemical properties of ramelteon(TAK-375), a selective MT1/MT2 receptor agonist.Neuropharmacology 2005;48:301-10.
[
DOI via Crossref]    [Pubmed]   

15.Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI.Molecular pharmacology, regulation and function of mammalian melatonin receptors.Fron Biosci 2003;1:1093-108.
[
DOI via Crossref]    [Pubmed]   

16.Cajochen C.TAK-375 Takeda.Curr Opin Investig Drugs 2005;6:114-21.
[
Pubmed]   

17.Miyamoto M, Nishikawa H, Doken Y, Hirai K, Uchikawa O, Ohkawa S.The sleep promoting action of ramelteon(TAK-375) in freely moving cats.Sleep 2004;27:1319-25.
[
Pubmed]   

18.Bellon A.Searching for New options for treating insomnia:are melatonin and ramelteon beneficial? J Psychiat Practice 2006;12:229-43.
[
DOI via Crossref]    [Pubmed]   

19.Stevenson S, Cornelissen K, Clarke E, Hibberd M.Study of the absorption, metabolism and excretion of(14C)–ramelteon(TAK-375).Clin Pharmacol Ther 2004;75:P22.
[
DOI via Crossref]   

20.Hibberd M, Stevenson SJ.A phase-1 open-label study of the absorption, metabolism, and excretion of(14C)–ramelteon(TAK-375) following a single oral dose in healthy male subjects.Sleep 2004;27:A54.


21.Greenblatt DJ, Harmatz JS, Karim A.Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2.J Clin Pharmacol 2007;47:485-96.
[
DOI via Crossref]    [Pubmed]   

22.Lavie P Melatonin:Role in gating nocturnal rise in sleep propensity.J Biol rhythms 1997;12:657-65.
[
DOI via Crossref]    [Pubmed]   

23.Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P.Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.Sleep Med 2006;7:312-8.
[
DOI via Crossref]    [Pubmed]   

24.Erman M, Seiden D, Zanmmit G, Sainati S, Zhang J.An efficacy, safety, and dose-response study of ramelteon in patients with chronic insomnia.Sleep Med 2006;7:17-24.
[
DOI via Crossref]    [Pubmed]   

25.Roth T, Seiden D, Wang-Weigand S, Zhang J.A 2 night, 3-period crossover study of ramelteon’s efficacy and safety in older subjects with chronic insomnia.Curr Med Res Opin 2007;23:1005-14.
[
DOI via Crossref]    [Pubmed]   

26.Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T.Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.J.Clin Sleep Med 2007;3:495-504.
[
Pubmed]    [PMC Free Fulltext]   

27.Zammit G, Schwartz H, Roth T, Wang-Weigand S, Sainati S, Zhang J.The effects of ramelteon in a first night model of transient insomnia.Sleep Med 2009;10:55-9.
[
DOI via Crossref]    [Pubmed]   

28.Mini L, Wang-Weigand S, Zhang J.Ramelteon 8 mg/day versus placebo in patients with chronic insomnia:post hoc analysis of a 5 week trial using 50% or greater reduction in latency to persistent sleep as a measurement of treatment effect.Clin Ther 2008;30:1316-23.
[
DOI via Crossref]   

29.Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M.Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.Sleep 2009;32:351-60.
[
Pubmed]    [PMC Free Fulltext]   

30.Dobkin RD, Menza M, Bienfait KL, Allen LA, Martin H, Gara MA.Ramelteon for the treatment of insomnia in menopausal women.Menopause Int 2009;15:13-8.
[
DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   

31.Zee PC, Wang-Weigand S, Wright KP Jr, Peng X, Roth T.Effects of ramelteon on insomnia symptoms induced by rapid eastward flight.Sleep Med 2010;11:525-33.
[
DOI via Crossref]    [Pubmed]   

32.Uchiyama M, Hamamura M, Kuwano T, Nishiyama H, Nagata H, Uchima N.Evaluation of subjective efficacy and safety oframelteon in Japanese subjects.Sleep Med 2011;12:119-26.
[
DOI via Crossref]    [Pubmed]   

33.Markwald RR, Lee-Chiong TL, Burke TM, Snider JA, Wright KP Jr.Effects of the melatonin MT1/MT2 agonist ramelteon on daytime body temperature and sleep.Sleep 2010;33:825-31.
[
Pubmed]    [PMC Free Fulltext]   

34.Kryger M, Wang-Weigand S, Roth T.Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea.Sleep Breath 2007;11:159-64.
[
DOI via Crossref]    [Pubmed]   

35.Kryger M, Wang-Weigand S, Zhang J, Roth T.Effects of ramelteon, a selective MT(1)/MT(2) receptor agonist on respiration during sleep in mild to moderate COPD.Sleep Breath 2008;12:243-50.
[
DOI via Crossref]    [Pubmed]   

36.van den Top M, Buijs RM, Ruijter JM, Delagrange P, Spanswick D, Hermes MI.Melatonin generates an outward potassium current in rat suprachiasmatic nucleus in vitro independent of their circadian rhythm.Neuroscience 2001;107:99-108.
[
DOI via Crossref]   

37.Edgar DM, Dement WC, Fuller CA.Effect of SCN lesions on sleep in squirrel monkeys:evidence for opponent processes in sleep-wake regulation.J Neurosci 1993;13:1065-79.
[
Pubmed]   

38.Yukuhiro N, Kimura H, Nishikawa H, Ohkawa S, Miyamoto M.Effects of ramelteon(TAK-375) on nocturnal sleep in freely moving monkeys.Brain Res 2004;1027:59-66.
[
DOI via Crossref]    [Pubmed]   

39.Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R Brown GM, Cardinali DP.Ramelteon:A review of its therapeutic potential in sleep disorders.Adv Ther 2009;26:613-26.
[
DOI via Crossref]    [Pubmed]   

40.Fuller PM, Gooley JJ, Saper CB.Neurobiology of the sleep-wake cycle:sleep architecture, circadian regulation, and regulatory feedback.J Biol Rhythms 2006;21:482-93.
[
DOI via Crossref]    [Pubmed]   

41.Yous S, Andrieux J, Howell HE, Morgan PJ, Renard P, Pfeiffer B, Lesieur D, Guardiola-Lemaitre B.Novel naphthalenic ligands with high affinity for the melatonin receptor.J Med Chem 1992;35:1484-5.
[
DOI via Crossref]    [Pubmed]   

42.Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V Rivet JM, Cussec D.The novel melatonin agonist agomelatine(S20098) is an antagonist at 5-hydroxytryptamine 2c receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.J Pharmacol Exp Ther 2003;308:954-84.
[
DOI via Crossref]    [Pubmed]   

43.Conway S, Canning SJ, Howell HE, Mowat ES, Barrett P, Drew JE, Delagrange P, Leisieur D, Morgan PJ.Characterization of human melatonin MT(1) and MT(2) receptors by CRE luciferase receptor assay.Eur J Pharmacol 2000;390:15-24.
[
DOI via Crossref]   

44.Bogaards JJ, Hissinik EM, Briggs M, Weaver R, Jochemsen R, Jackson R, Bertrand M, van Bladeren PJ.Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling.Eur J Pharm Sci 2000;12:117-24.
[
DOI via Crossref]   

45.Kupfer Dj, Spiker DG, Coble PA, Neil JF, Ulrich R, Shaw DH.Sleep and treatment prediction in endogenous depression.Am J Psychiatry 1981;138:429-34.
[
Pubmed]   

46.Kupfer DJ.Depression and associated sleep disturbances:patient benefits with agomelatine.Eur Neuropsychopharmacol 2006;16(suppl 5):S639-43.
[
DOI via Crossref]   

47.Loo H, Hale A, D’haenen H.Determination of the dose of agomelatine, a melatoninergic antidepressant and selective 5-HT2c antagonist in the treatment of major depressive disorder:a placebo controlled dose range study.Int Clin Psychopharmacol 2002;17:239-47.
[
DOI via Crossref]   

48.Kennedy SH, Emsley R.Placebo controlled trial of agomelatine in the treatment of major depressive disorder.Eur Neuropsychopharmacol 2006;16:93-100.
[
DOI via Crossref]    [Pubmed]   

49.Pjrek F, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, Kasper S.Agomelatine in the treatment of seasonal affective disorder.Psychopharmacology 2007;190:575-9.
[
DOI via Crossref]    [Pubmed]   

50.Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A.Agomelatine in the treatment of major depressive disorder:an 8 week, multicenter, randomized, placebo controlled trial.J Clin Psychiatry 2010;71:616-26.
[
DOI via Crossref]    [Pubmed]   

51.Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V.Superior anti-depressant efficacy:Results of agomelatine versus fluoxetine in severe MDD patients:a randomized, double blind study.Int J Clin Psychopharmacol 2010;25:305-14.
[
DOI via Crossref]    [Pubmed]   

52.Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Querra-Salva MA, et al.Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive, and anxiety symptoms in patients with major depressive disorder:a randomized double blind comparison with sertraline.J Clin Psychiatry 2010;71:109-20.
[
DOI via Crossref]    [Pubmed]   

53.De Beradis D, Di Lorio G, Accivatti T, Conti C, Serroni N, Olivierri L, Cavuto M, Martinotti G, Janiri L, Moschetta FS, Conti P, Giannantonio M.The emerging role of melatonin agonists in the treatment of depression:focus on agomelatine.CNS Neurol Disor Drug Targets 2010;10:119-32.
[
DOI via Crossref]   

54.Srinivasan V, Brzezinski D, Spence DW, Pandi-Perumal SR, Hardeland R, Brown GM Cardinali DP.Sleep, mood disorders and antidepressants:the melatonergic antidepressant offers a new strategy of treatment.Psychiatria Fennica 2010;41:147-58.


55.Lam RW.The importance of early symptom relief in antidepressant treatment focus on agomelatine.J Psychopharmacol 2010;24(2 Suppl):27-30.
[
DOI via Crossref]    [Pubmed]   

56.Quera-Salva MA, Vanier B, Chapotot F, Bohic M, Andre S, Moulin C, Lofaso F, Guilleminault C.Effect of agomelatine on the sleep EEG in patients with major depressive disorder(MDD).Eur Neuropsychopharmacol 2005;15:S435-6.
[
DOI via Crossref]   

57.Guillenminault C.Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder.Eur Neuropsychopharmacol 2005;15(Suppl 3):419.
[
DOI via Crossref]   

58.Quera-Salva MA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C, Lofaso F, Guilleminault C.Major depressive disorder, sleep EEG and agomelatine:an open-label study.Int J Neuropsychopharmacol 2007;10:691-6.
[
Pubmed]   

59.Zupancic M, Guilleminault C.Agomelatine:a preliminary review of a new antidepressant.CNS Drugs 2006;20:981-92.
[
DOI via Crossref]    [Pubmed]   

60.Boivin DB.Influence of sleep wake cycle and circadian rhythms disturbances in psychiatric in psychiatric disorders.J Psychiatry Neurosci 2000;25:446-58.
[
Pubmed]    [PMC Free Fulltext]   

61.Rouillon F.Efficacy and tolerance profile of agomelatine and practical use in depressed patients.Int Clin Psychopharmacol 206;21(Suppl 1):S31-5.


62.Jindal RD, Thase ME.Treatment of insomnia associated with clinical depression.Sleep Med 2004;8:19-30.
[
DOI via Crossref]   

63.Fuchs E, Simon M, Schmelting B.Pharmacology of a new antidepressant:benefit of the implication of the melatonergic system.Int Clin Psychopharmacol 2006;21(Suppl 1):S17-20.
[
DOI via Crossref]    [Pubmed]   

64.Bertaina-Anglade V, La Rochelle CD, Boyer PA, Mocaer E.Antidepressant-like effects of agomelatine(S20098) in the learned helplessness model.Behavioural Pharmacology 2006;17:703-13.
[
DOI via Crossref]    [Pubmed]   

65.Liu C, Weaver DR, Jin X, Shearman IP, Pieschl RL, Gribkoff VK, Reppert SM.Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock.Neuron 1997;19:91-102.
[
DOI via Crossref]   

66.Weill ZM, Hotchkiss AK, Gatier ML, Pieke-Dahls S, Nelson RJ.Melatonin receptor(MT1) knockout mice display depression like behaviours and defecits in sensorimotor gating.Brain Res Bull 2006;68:425-9.
[
DOI via Crossref]    [Pubmed]   

67.Strauss WH, Klieser E.Psychotrophic effects of ritanserin, a selective S2 antagonist:an open study.Eur Neuropsychopharmacol 1991;1:101-5.
[
DOI via Crossref]   

68.Niswender CM, Herrick-davis K, Dilley GE, Meltzer HY, Overholster JC, Stockmeier CA, Emerson RB, Sanders-Bush E.RNA-editing of the human serotonin 5-HT2C receptor.Alterations in suicide and implications for serotonergic pharmacotherapy.Neuropsychopharmacology 2001;24:478-91.
[
DOI via Crossref]   

69.Gurevich I, Tamir H, Arango V, Dwork AJ, Mann JJ, Schumauss C.Altered editing of serotonin serotonin 2C receptors pre-mRNA in the prefrontal cortex of depressed suicide victims.Neuron 2002;34:349-6.
[
DOI via Crossref]   

70.Iwamoto K, Kato T.RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders.Neurosci Lett 2003;346:169-72.
[
DOI via Crossref]   

71.Dubocovich M Drug evaluation:Agomelatine targets a range of major depressive disorder symptoms.Curr Opin Investigational Drugs 2006;7:670-80.
[
Pubmed]   

72.Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A.Prevalence of sexual dysfunction among newer antidepressants.J Clin Psychiatry 2002;63:357-66.
[
DOI via Crossref]    [Pubmed]   

73.Rothschild AJ.Sexual side effects of antidepressants.J Clin Psychiatry 2000;61(Suppl 1):28-36.
[
Pubmed]   

74.Montejo Al, Llorca G, Izquierdo JA, Rico-Villaemororos F.Incidence of sexual dysfunction associated with antidepressant agents:A prospective multicenter study of 1022 outpatients.J Clin Psychiatry 2001;62(Suppl 3):10-21.


75.Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I.Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine:a randomized, double blind, placebo-controlled discontinuation study.Int Clin Psychopharmacol 2004;19:271-80.
[
DOI via Crossref]    [Pubmed]   

76.Winokur A, Gary KA, Rodner S, Rae-Red C, Fernado AT, Szuba MP.Depression, sleep physiology, and antidepressant drugs.Depressi Anxiety 2001;14:19-28.
[
DOI via Crossref]    [Pubmed]   

77.Wilson S.Antidepressants and sleep.A qualitative review of the literature.Drugs 2005;65:927-47.
[
DOI via Crossref]    [Pubmed]   

78.Srinivasan V, Pandi-Perumal SR, Trakht I, Spence DW, Hardeland R, Poeggeler B, Cardinali DP.Pathophysiology of depression:role of sleep and the melatonergic system.Psychiat Res 2009;165:201-14.
[
DOI via Crossref]    [Pubmed]   

79.Dubocovich ML.Pharmacology and function of melatonin receptors.FASEB J 1988;2:2765-73.
[
Pubmed]   

80.Nosjean O, Ferro, Coge F, Beauverger P, Henlin JM, Lefoulin F, Fauchere JL, Delagrange P, Canet E, Boutin JA.Identification of the melatonin-binding site MT3 as the quinine reductase 2.J Biol chem.2000;275:31311-7.
[
DOI via Crossref]    [Pubmed]   

81.Malliet F, Ferry G, Vella F, Thiam K, Delagrange P, Boutin JA.Organs from mice deleted for NRH quinone oxido reductase 2 are deprived of the melatonin binding site MT3.FEBS Lett 2004;578:116-20.
[
DOI via Crossref]    [Pubmed]   

82.Harada S, Fujii C, Hayashi A, Ohkoshi N.An association between idiopathic Parkinson’s disease and polymorphisms of phase II detoxification enzymes:glutathione-S-transferase M1 and quinine oxidoreductases 1 and 2.Biochem Biophys Res Commun 2001;288:887-92.
[
DOI via Crossref]    [Pubmed]   

83.Harada S, Tachikawa H, Kawanshi Y.A possible association between an insertion/deletion polymorphism of the NQO2 gene and schizophrenia.Psychiat Genetics 2003;13:205-9.
[
DOI via Crossref]    [Pubmed]   

84.Serle JB, Wang RF, Peterson WM, Plourde R, Yerxa BR.Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist on intraocular pressure in glaucomatous monkey eyes.J Glaucoma 2004;13:385-8.
[
DOI via Crossref]    [Pubmed]   

85.Oxenkrug GF, Bachurin SO, Prakhie W, Zefirov NS.Quinone reductase 2 and antidepressant effect of melatonin derivatives.Ann NY Acad Sci 2010;1199:121-4.
[
DOI via Crossref]    [Pubmed]   

This Article Cited By the following articles


2016; (): 381.

1
 
Melatonin: a ā€œHiggs bosonā€ in human reproduction
Gynecol Endocrinol 2015; 31(2): 92.

2
 
Development and validation a LCā€“MS/MS method for the simultaneous determination of agomelatine and its metabolites, 7-desmethyl-agomelatine and 3-hydroxy-agomelatine in human plasma: Application to a bioequivalence study
Journal of Chromatography B 2015; 1003(): 60-66.

3
 
Possible Role of Exogenous Melatonin and Melatonin-Receptor-Agonists in the Treatment of Menopauseā€•Associated Sleep Disturbances
Open Journal of Obstetrics and Gynecology 2014; 04(06): 309-320.

4
 
Synthetic Melatoninergic Ligands: Achievements and Prospects
ISRN Biochemistry 2014; 2014(): 1.

5
 
Plasma Melatonin and Urinary 6-Hydroxymelatonin Levels in Patients with Pulmonary Tuberculosis
Inflammation 2012; 35(4): 1429-1434.

6
 
Melatonin and its analogs in insomnia and depression
Journal of Pineal Research 2012; 52(4): 365-375.

7
 
Hemochromatosis and bipolar disorder
General Hospital Psychiatry 2012; 34(4): 433.

8
 
Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action
The Journal of Neuropsychiatry and Clinical Neurosciences 2012; 24(3): 290-308.

9
 

How to Cite this Article
Pubmed Style

Srinivasan V, Cardinali DP, Pandi-Perumal SR, Brown GM. Melatonin agonists for treatment of sleep and depressive disorders. J Exp Integr Med. 2011; 1(3): 149-158. doi:10.5455/jeim.100511.ir.005



Web Style

Srinivasan V, Cardinali DP, Pandi-Perumal SR, Brown GM. Melatonin agonists for treatment of sleep and depressive disorders. www.scopemed.org/?mno=6160 [Access: August 18, 2017]. doi:10.5455/jeim.100511.ir.005



AMA (American Medical Association) Style

Srinivasan V, Cardinali DP, Pandi-Perumal SR, Brown GM. Melatonin agonists for treatment of sleep and depressive disorders. J Exp Integr Med. 2011; 1(3): 149-158. doi:10.5455/jeim.100511.ir.005



Vancouver/ICMJE Style

Srinivasan V, Cardinali DP, Pandi-Perumal SR, Brown GM. Melatonin agonists for treatment of sleep and depressive disorders. J Exp Integr Med. (2011), [cited August 18, 2017]; 1(3): 149-158. doi:10.5455/jeim.100511.ir.005



Harvard Style

Srinivasan, V., Cardinali, D. P., Pandi-Perumal, S. R. & Brown, G. M. (2011) Melatonin agonists for treatment of sleep and depressive disorders. J Exp Integr Med, 1 (3), 149-158. doi:10.5455/jeim.100511.ir.005



Turabian Style

Srinivasan, Venkataramanujan, Daniel P. Cardinali, Seithikurippu R. Pandi-Perumal, and Gregory M. Brown. 2011. Melatonin agonists for treatment of sleep and depressive disorders. Journal of Experimental and Integrative Medicine, 1 (3), 149-158. doi:10.5455/jeim.100511.ir.005



Chicago Style

Srinivasan, Venkataramanujan, Daniel P. Cardinali, Seithikurippu R. Pandi-Perumal, and Gregory M. Brown. "Melatonin agonists for treatment of sleep and depressive disorders." Journal of Experimental and Integrative Medicine 1 (2011), 149-158. doi:10.5455/jeim.100511.ir.005



MLA (The Modern Language Association) Style

Srinivasan, Venkataramanujan, Daniel P. Cardinali, Seithikurippu R. Pandi-Perumal, and Gregory M. Brown. "Melatonin agonists for treatment of sleep and depressive disorders." Journal of Experimental and Integrative Medicine 1.3 (2011), 149-158. Print. doi:10.5455/jeim.100511.ir.005



APA (American Psychological Association) Style

Srinivasan, V., Cardinali, D. P., Pandi-Perumal, S. R. & Brown, G. M. (2011) Melatonin agonists for treatment of sleep and depressive disorders. Journal of Experimental and Integrative Medicine, 1 (3), 149-158. doi:10.5455/jeim.100511.ir.005